TD Cowen and Citigroup raise West Pharmaceutical targets to $500 and $494
TD Cowen and Citigroup kept Buy ratings on West Pharmaceutical Services and raised price targets to $500 and $494 after the October 30 close.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
TD Cowen kept its Buy rating on West Pharmaceutical Services and lifted its target to $500 from $420, a jump of 19.0%, according to TradingView, which relays Benzinga data. That level sits 21.2% above the October 30 close of $412.62.
Citigroup, in a separate note the same day, also kept Buy and raised its target to $494 from $412, a gain of 19.9%. That figure implies 19.7% upside from the same closing price.
why it matters
Two large banks lifting their targets on the same stock in one session points to a more optimistic analyst view of the company. Updates like these mostly affect the shares themselves and rarely move the broader market.
tags
instruments
sources
- TD Cowen maintains West Pharmaceutical Servs at Buy, raises price target to $500 from $420 — TradingView, 30 October 2026 at 20:29 UTC
- Citigroup maintains West Pharmaceutical Servs at Buy, raises price target to $494 from $412 — TradingView, 30 October 2026 at 20:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗